Written by admin on 12:24 AM
Cardiovascular diseases are one of the most important causes of death in our country. A high cholesterol in the blood has always been considered a major risk factor.
Since the 90 years, we have medicines, called "hypolipemiants", effective in the fight against excess cholesterol in the blood.
To promote judicious use of these drugs very expensive, repayment thereof was subject to specific rules, with the need for prior authorization of the medical board. Thus, the use of anti cholesterol drugs was allowed only after verifying that a more balanced diet did not allow the patient to lower his cholesterol.
Until now, permission for access to hypolipemiants therefore was based solely on cholesterol. However, scientific work has highlighted the importance of many other factors. The age, family history, hereditary predisposition, smoking, diabetes, high blood pressure, cardiovascular disease are all risk factors.
That is why new criteria for reimbursement have been developed and entered into force on 1 December 2003.
All hypolepimiants (both original medicines that generic drugs) are still reimbursed through a prior agreement of the medical council of the mutual, but according to a simplified procedure proposed by the Christian Mutualité. The doctor will use a standardized form that allows it to easily certify the different elements that come into play to confirm that an anti cholesterol treatment is necessary (and no longer the only cholesterol). Accordingly, it is possible that the use of drugs anti cholesterols no longer justified for some patients, current scientific evidence has shown that they were wrongly placed in a category "at risk".
The situation of each patient should be reassessed, calmly, by his doctor, according to new criteria. However, to allow patients and doctors time that the revaluation is made, the Mutualité Christian has been approved in principle that for the treatments currently underway, permits issued before 1 December 2003 will retain their validity until the date End of the period mentioned on the authorization
The Mutualité Christian failed to get at this time a decrease in the price of anti cholesterol drugs, but the Minister assured that this will happen in a second time, following our proposal to combine a large decrease in price with the deletion of prior recourse to the medical board. By the Mutualité against Christian is satisfied that the terms of repayment be made in accordance with the latest scientific knowledge.